Global trade dynamics are shifting, leading biotech and pharma companies to rethink how and where their medicines are made. For many, that means strengthening supply chains, reducing reliance on overseas networks, and investing in more resilient, regionally aligned manufacturing strategies.
At Thermo Fisher Scientific, we continue to make significant investments in our U.S. network to help customers meet these challenges. Our expanding footprint of development and manufacturing sites reflects a long-term commitment to strengthening domestic supply for critical therapies across modalities and platforms.
With integrated capabilities spanning early development through commercial production, we’re helping customers navigate uncertainty and build a more reliable path to market.
Watch the video to see how our U.S. network is designed to minimize disruption and keep progress moving.